Disease · MONDO_0005240

kidney disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. kidney disorder. Diseases, record MONDO_0005240. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005240

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: kidney disorder; Open Targets
Open Targets ID: MONDO_0005240; Open Targets
Other names: disease of kidney, disease or disorder of kidney, disorder of kidney, kidney disease, kidney disease or disorder, kidney diseases, nephropathy, renal disease, renal disorder, renal system disease; Open Targets
Disease Ontology: DOID:557; Disease Ontology
MeSH: D007674; MeSH
NCI Thesaurus: C3149; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 86 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs86

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LOSARTAN POTASSIUM	CHEMBL995	Small molecule	Approval	DailyMed	48	0	0	Drugs and targets
BUMETANIDE	CHEMBL1072	Small molecule	Approval	DailyMed and FDA	23	0	0	Drugs and targets
ALUMINUM CHLOROHYDRATE	CHEMBL2109016		Approval	DailyMed	1	0	0	Drugs and targets
AMINOHIPPURATE SODIUM	CHEMBL1200365	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ICODEXTRIN	CHEMBL1201472		Approval	TTD	1	0	0	Drugs and targets
SEVELAMER HYDROCHLORIDE	CHEMBL1201492	Small molecule	Approval	FDA	1	0	0	Drugs and targets
CALCIFEDIOL	CHEMBL3544909	Small molecule	Preapproval	TTD	1	0	0	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
LOSARTAN	CHEMBL191	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 86

See all 86 drugs

Targets138

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	6	Insulin receptor agonist	Unknown	https://conductscience.org/library/genes/3643	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	5	Sodium/glucose cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6524	Drugs and targets
DPP4	Dipeptidyl peptidase 4	4	Dipeptidyl peptidase IV inhibitor	Phase 1	https://conductscience.org/library/genes/1803	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	4	Glucagon-like peptide 1 receptor agonist	Phase 2	https://conductscience.org/library/genes/2740	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	3	Sulfonylurea receptor 1, Kir6.2 blocker	Unknown	https://conductscience.org/library/genes/6833	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	3	Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 1	https://conductscience.org/library/genes/2057	Drugs and targets
KCNJ11	Sulfonylurea receptor 1, Kir6.2	3	Sulfonylurea receptor 1, Kir6.2 blocker	Unknown	https://conductscience.org/library/genes/3767	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
ACE	Angiotensin-converting enzyme	2	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets

1 to 10 of 138

See all 138 targets

Trials55

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05465317	Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease		62,197	2024-09-19	Diabetes Mellitus, Type 2	EMPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT00555217	VA NEPHRON-D: Diabetes iN Nephropathy Study	Phase 3	1,448	2015-05-29	Kidney Disease, Nephropathy, Type 2 Diabetes	LISINOPRIL ANHYDROUS, LOSARTAN	Its record names the disease	ClinicalTrials.gov
NCT01082640	Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment	Phase 2	96	2013-09-25	Renal Impairment	FEBUXOSTAT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00982423	The Effects of Decreasing the Lasix Dose on the Cardiorenal System	Phase 1/2	41	2015-07-20	Heart Failure, Kidney Dysfunction	FUROSEMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03285711	Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)	Phase 2	9	2020-05-18	Lupus Membranous Nephropathy	FILGOTINIB, LANRAPLENIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01302899	To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy	Phase 2	8	2013-01-30	Non-diabetic Nephropathy	ALISKIREN, HYDROCHLOROTHIAZIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00424749	Rituxan in Churg Strauss Syndrome With Renal Involvement	Phase 2	4	2011-12-08	Churg-Strauss Syndrome	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT05161429	BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes		550,000		Diabetes Mellitus, Type 2	ALOGLIPTIN, CANAGLIFLOZIN, DAPAGLIFLOZIN, DULAGLUTIDE, EMPAGLIFLOZIN, ERTUGLIFLOZIN, EXENATIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE, INSULIN DETEMIR, INSULIN GLARGINE, LINAGLIPTIN, LIRAGLUTIDE, SAXAGLIPTIN, SEMAGLUTIDE, SITAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT05535322	Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity		26,944		Type 2 Diabetes, Obesity	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00308347	A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)	Phase 3	1,513		Type 2 Diabetes, Nephropathy	LOSARTAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 55

See all 55 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Empagliflozin Initiators vs Dipeptidyl Peptidate-4 Inhibitor (DPP4i) Initiators: deaths from any cause	341 of 20,279	1,528 of 41,918	62,197	NCT05465317	Trial comparisons
Combination of ARB and ACEI vs Monotherapy ARB: A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73mm in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73mm, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death	132 of 724	152 of 724	1,448	NCT00555217	Trial comparisons
Combination of ARB and ACEI vs Monotherapy ARB: A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD.	77 of 724	101 of 724	1,448	NCT00555217	Trial comparisons
Combination of ARB and ACEI vs Monotherapy ARB: serious adverse events	416 of 724	380 of 724	1,448	NCT00555217	Trial comparisons
Compensated CHF Without Renal Dysfunction vs Compensated CHF With Renal Dysfunction: serious adverse events	0 of 13	2 of 19	32	NCT00982423	Trial comparisons

Papers from its trials44

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42027554	RESULT	1	PubMed
25262369	RESULT	1	PubMed
25157242	RESULT	1	PubMed
25014549	RESULT	1	PubMed
24552328	RESULT	1	PubMed
24206457	RESULT	1	PubMed
21325353	RESULT	1	PubMed
19216016	RESULT	1	PubMed
42925875	DERIVED	1	PubMed
42789922	DERIVED	1	PubMed

1 to 10 of 44

See all 44 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005240

GET https://conductscience.org/api/diseases/v1/MONDO_0005240/drugs?page=2

API reference For AI assistants